Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Pharm Sci ; 71(9): 1008-10, 1982 Sep.
Article in English | MEDLINE | ID: mdl-6127399

ABSTRACT

The placental transfer of ranitidine was studied at pharmacokinetic steady state in anesthetized, full-term, pregnant sheep. Ranitidine was administered to the ewe in three preparations and to the fetus in three other sheep. In all experiments, dose size was based on the combined maternal-fetal weight. Steady-state plasma levels were reached within 4 hr by using an initial intravenous bolus dose followed by continuous infusion. Following maternal dosage, the mean maternal (jugular vein) steady-state concentration (CMss) at 4 hr was 842 +/- 66 ng/ml (SEM), the mean fetal (carotid artery) steady-state concentration (CFss) was 26.5 +/- 4.2 ng/ml, and the mean fetal umbilical venous steady-state concentration was 28.9 +/- 3.5 ng/ml. Both the fetal and umbilical plasma concentrations were significantly less than the maternal plasma concentrations (p less than 0.01). With fetal dosage, mean CMss was 414 +/- 42 ng/ml at 4 hr and was significantly less than the mean CFss value at the same time, which was 6890 +/- 360 ng/ml (p less than 0.005). Ranitidine was not bound extensively to plasma proteins in the ewe or the fetus (range 12-55% bound). The reversal of the CMss/CFss gradient with the change from maternal to fetal administration and the low binding of the drug shows that the gradient following maternal dosage cannot be explained by ion-trapping or differential plasma protein binding. As active placental transport is considered unlikely, the low fetal plasma concentrations are probably due to the presence of significant fetal elimination of ranitidine. Furthermore, the substantial gradient between maternal and umbilical venous plasma concentrations suggests that placental elimination of ranitidine should also be considered.


Subject(s)
Furans/metabolism , Histamine H2 Antagonists/metabolism , Animals , Female , Fetus/metabolism , Furans/administration & dosage , Histamine H2 Antagonists/administration & dosage , Infusions, Parenteral , Maternal-Fetal Exchange , Pregnancy , Protein Binding , Ranitidine , Sheep , Time Factors
2.
J Pharm Sci ; 71(5): 590-2, 1982 May.
Article in English | MEDLINE | ID: mdl-7097510

ABSTRACT

An assay is described for the determination of the H2-receptor antagonist, cimetidine, in human plasma and urine. Alkalinized plasma or urine was extracted with methylene chloride, the organic phase was evaporated, and the reconstituted residue was analysed by high-pressure liquid chromatography (HPLC) using a reversed-phase prepacked plastic column housed in a radial compression module. The metabolite, cimetidine sulfoxide, was identified but could not be quantitated due to interference from the solvent front. The sensitivity limit of the assay was 25 ng/ml. The assay was applied to the measurement of plasma and urine samples in a pilot pharmacokinetic study. Cimetidine was substantially absorbed and rapidly eliminated (plasma elimination half-life of 112-130 min). Plasma cimetidine concentrations could be measured to 12 hr after a 200-mg dose (iv or oral), but they were below the sensitivity of the assay by 24 hr. Urinary excretion of unmetabolized cimetidine accounted for 40-50% of the administered dose in the first 12 hr. This assay is simpler and more sensitive than those previously described, and it is suitable for the measurement of cimetidine in plasma and urine of subjects receiving doses appropriate for clinical use.


Subject(s)
Cimetidine/analysis , Guanidines/analysis , Chromatography, High Pressure Liquid/methods , Cimetidine/blood , Cimetidine/urine , Humans , Kinetics , Spectrophotometry, Ultraviolet/methods
3.
Am J Physiol ; 238(1): G10-7, 1980 Jan.
Article in English | MEDLINE | ID: mdl-7356024

ABSTRACT

The effect of four bile acids, taurocholic (TC), taurochenodeoxycholic (TCDC), tauro-3 alpha,7 alpha-dihydroxy-12-keto-5 beta-cholanoic (T12K), and cholic (C), on bile lipid and water secretion was studied in the bile fistula cat over a 20-fold range of bile acid secretion rates. The critical micellar concentration (CMC) and lecithin-solubilizing capacity of TC, TCDC, and T12K were measured in vitro. T12K and C produced a greater choleresis than TC or TCDC; phospholipid secretion was strikingly reduced with T12K; and cholesterol secretion strikingly increased with TCDC, with a high cholesterol-phospholipid ratio. The estimated CMCs of TC, TCDC, and T12K were 3.3, 0.7, and 6.2 mM respectively; the relative lecithin-solubilizing capacities were 4.4:2.6:1. We conclude that the micellar characteristics of the bile acids studied do not explain the differences in water and lipid secretion observed, and that effects within the hepatocyte may be equally important.


Subject(s)
Bile Acids and Salts/pharmacology , Bile/metabolism , Body Water/metabolism , Cholesterol/metabolism , Phosphatidylcholines/metabolism , Phospholipids/metabolism , Animals , Bile Acids and Salts/administration & dosage , Cats , Cholic Acids/pharmacology , Infusions, Parenteral , Taurocholic Acid/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...